On 14 April 2019, orphan designation (EU/3/19/2154) was granted by the European Commission to Takeda Pharma A/S, Denmark, for balipodect for the treatment of fragile X syndrome.
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.